Birch Hill Investment Advisors LLC Trims Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Birch Hill Investment Advisors LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,513 shares of the medical equipment provider’s stock after selling 655 shares during the period. Birch Hill Investment Advisors LLC’s holdings in Zimmer Biomet were worth $1,744,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet in the third quarter valued at $28,000. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet during the third quarter worth about $35,000. R Squared Ltd purchased a new position in shares of Zimmer Biomet during the fourth quarter worth about $63,000. Finally, Mather Group LLC. raised its stake in Zimmer Biomet by 100.9% during the 4th quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock valued at $70,000 after acquiring an additional 332 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $101.01 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $99.93 and a fifty-two week high of $133.90. The stock has a fifty day moving average of $107.34 and a two-hundred day moving average of $108.10. The company has a market capitalization of $20.11 billion, a price-to-earnings ratio of 22.70, a PEG ratio of 1.83 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the business posted $2.20 earnings per share. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.95%. Zimmer Biomet’s payout ratio is currently 21.57%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ZBH. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Friday. Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Raymond James dropped their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday. Oppenheimer reduced their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Finally, JMP Securities reiterated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $124.70.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.